KR101455447B1 - Ｍｕｃ１＊ 항체 - Google Patents

Ｍｕｃ１＊ 항체 Download PDF

Info

Publication number
KR101455447B1
KR101455447B1 KR1020117010349A KR20117010349A KR101455447B1 KR 101455447 B1 KR101455447 B1 KR 101455447B1 KR 1020117010349 A KR1020117010349 A KR 1020117010349A KR 20117010349 A KR20117010349 A KR 20117010349A KR 101455447 B1 KR101455447 B1 KR 101455447B1
Authority
KR
South Korea
Prior art keywords
seq
ser
sequence
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117010349A
Other languages
English (en)
Korean (ko)
Other versions
KR20110067153A (ko
Inventor
산지브 마한타
신디아 밤다드
Original Assignee
미네르바 바이오테크놀로지 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미네르바 바이오테크놀로지 코포레이션 filed Critical 미네르바 바이오테크놀로지 코포레이션
Publication of KR20110067153A publication Critical patent/KR20110067153A/ko
Application granted granted Critical
Publication of KR101455447B1 publication Critical patent/KR101455447B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117010349A 2008-10-06 2009-10-06 Ｍｕｃ１＊ 항체 Active KR101455447B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10320408P 2008-10-06 2008-10-06
US61/103,204 2008-10-06
PCT/US2009/059754 WO2010042562A2 (en) 2008-10-06 2009-10-06 Muc1* antibodies

Publications (2)

Publication Number Publication Date
KR20110067153A KR20110067153A (ko) 2011-06-21
KR101455447B1 true KR101455447B1 (ko) 2014-10-27

Family

ID=42101177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117010349A Active KR101455447B1 (ko) 2008-10-06 2009-10-06 Ｍｕｃ１＊ 항체

Country Status (8)

Country Link
US (4) US10421819B2 (enExample)
EP (3) EP4083072B1 (enExample)
JP (3) JP2012504961A (enExample)
KR (1) KR101455447B1 (enExample)
CN (1) CN102239182B (enExample)
CR (1) CR20110238A (enExample)
IL (1) IL212175B (enExample)
WO (1) WO2010042562A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421819B2 (en) 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
KR101853418B1 (ko) * 2010-06-16 2018-05-02 미네르바 바이오테크놀로지 코포레이션 암 세포의 역분화
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
WO2012126013A2 (en) * 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN102716472A (zh) * 2011-03-31 2012-10-10 李光辉 一种肿瘤疫苗及其合成方法
JP6748430B2 (ja) * 2012-07-13 2020-09-02 ミネルバ バイオテクノロジーズ コーポレーション より未分化状態への細胞の誘導方法
CA2882222A1 (en) * 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
EP2900275A4 (en) * 2012-09-29 2016-05-25 Univ Pennsylvania VETERINARY COMPOSITION AND METHOD FOR NONOPERATIVE CASTRATION
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
WO2014114298A1 (en) * 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
ES2794088T3 (es) 2014-01-29 2020-11-17 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD)
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
SG10201808867PA (en) 2014-04-07 2018-11-29 Minerva Biotechnologies Corp Anti-nme antibody
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN107001471B (zh) * 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
KR20170063881A (ko) 2014-10-02 2017-06-08 시티 오브 호프 다가 메디토프, 메디토프 결합 항체 및 이의 용도
EP3204414B1 (en) 2014-10-07 2024-12-04 Ann and Robert H. Lurie Children's Hospital of Chicago Novel anti-nodal antibodies and methods of using same
CA2976089C (en) * 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CA3007646A1 (en) * 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
EP3450460B1 (en) * 2016-04-29 2023-07-12 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
WO2018138113A1 (en) * 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
MX2019012233A (es) * 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
CN109971713B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途
IL276464B2 (en) * 2018-02-07 2026-01-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
US20200405832A1 (en) * 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
KR20220016802A (ko) 2019-02-04 2022-02-10 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
US12049514B2 (en) 2020-06-08 2024-07-30 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
WO2021263227A2 (en) * 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN117693530A (zh) * 2020-07-16 2024-03-12 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域（muc1-c/ecd）的抗体
WO2022026809A1 (en) 2020-07-31 2022-02-03 R.P. Scherer Technologies, Llc Antibody specific for mucin-1 and methods of use thereof
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
KR20250126852A (ko) * 2023-01-04 2025-08-25 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-muc1 항체 및 이의 용도
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025080693A1 (en) 2023-10-11 2025-04-17 Minerva Biotechnologies Corporation Anti-muc1* antibody drug complexes and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235868A1 (en) * 2002-04-22 2003-12-25 Dyax Corporation Antibodies specific for mucin polypeptide
US20060222637A1 (en) * 2005-03-30 2006-10-05 Bamdad Cynthia C Proliferation of muc1 expressing cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020136725A1 (en) * 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
RU2227752C2 (ru) 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
WO2002000255A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
CA2421751C (en) 2000-09-11 2014-02-11 Donald W. Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
CA2442531A1 (en) 2001-03-29 2002-10-10 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and antibodies to muc 1 proteins
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
CA2478047C (en) * 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
CA2489467C (en) * 2002-06-14 2015-02-24 Immunomedics, Inc. Humanized monoclonal antibody hpam4
EP2363410B1 (en) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
WO2005080432A2 (en) * 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
KR101252306B1 (ko) * 2004-10-04 2013-04-08 제넨테크, 인크. 간세포 성장 인자 활성화제의 조정제
CN101652469B (zh) 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
US8420591B2 (en) * 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
US10421819B2 (en) 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
CA2882222A1 (en) * 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
CA2976089C (en) * 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235868A1 (en) * 2002-04-22 2003-12-25 Dyax Corporation Antibodies specific for mucin polypeptide
US20060222637A1 (en) * 2005-03-30 2006-10-05 Bamdad Cynthia C Proliferation of muc1 expressing cells

Also Published As

Publication number Publication date
EP4083072A1 (en) 2022-11-02
IL212175A0 (en) 2011-06-30
CN102239182A (zh) 2011-11-09
US20170204191A1 (en) 2017-07-20
US11560435B2 (en) 2023-01-24
IL212175B (en) 2019-08-29
CN102239182B (zh) 2014-07-09
CR20110238A (es) 2012-05-29
US10421819B2 (en) 2019-09-24
EP2337801A2 (en) 2011-06-29
EP2337801A4 (en) 2012-07-25
JP6230983B2 (ja) 2017-11-15
US20230295340A1 (en) 2023-09-21
EP3130607B1 (en) 2024-04-17
EP3130607A2 (en) 2017-02-15
WO2010042562A2 (en) 2010-04-15
KR20110067153A (ko) 2011-06-21
JP6392923B2 (ja) 2018-09-19
US20200239594A1 (en) 2020-07-30
US20180222998A1 (en) 2018-08-09
EP3130607A3 (en) 2017-06-28
JP2012504961A (ja) 2012-03-01
JP2015071614A (ja) 2015-04-16
EP4083072B1 (en) 2026-02-18
WO2010042562A3 (en) 2010-09-30
JP2017176174A (ja) 2017-10-05

Similar Documents

Publication Publication Date Title
KR101455447B1 (ko) Ｍｕｃ１＊ 항체
KR102924006B1 (ko) 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
KR102365972B1 (ko) 항-pd-1 항체 및 이의 용도
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
CN112574310B (zh) 抗SIRPα抗体及其用途
JP2026001061A (ja) 抗ｄｌｌ３キメラ抗原受容体及びその使用
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
KR20140018837A (ko) 노텀 단백질 조절 인자 및 사용 방법
CN109776677B (zh) 一种人源化抗il-13抗体及其制备方法和应用
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN115386006A (zh) 抗gprc5d抗体、其制备方法与用途
US20240018255A1 (en) ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
CN117164719A (zh) 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用
HK40082756A (en) Muc1* antibodies
CN114773467B (zh) 抗SIRPα抗体或其抗原结合片段及应用
KR101599370B1 (ko) Jagged 1에 대한 인간 단일클론항체 J1J22
CN119698435A (zh) 抗ilt4抗体及其医药用途
HK40016537B (zh) 抗pd-1抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111028

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130527

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130527

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20131127

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20111028

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20140721

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20140623

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20140321

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20131127

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20111028

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141021

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141021

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181001

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181001

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190926

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190926

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20211202

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20231011

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20241008

Start annual number: 11

End annual number: 11